Our global R&D resources platform is a collaboration of efforts between Hepalink R&D Center, Cytovance® Biologics CDMO R&D business teams and various third-party cooperative R&D efforts, which are capable of meeting clinical and market demands. Hepalink’s R&D center focuses on the clinical development of its own innovative drugs - heparin derivatives - and provides technical support for our commercialized pharmaceutical products. The CDMO business R&D platform, located in North America provides comprehensive development and manufacturing services for late discovery to commercial stage biologic therapeutic . We also develop a series of first-in-class drug candidates through our new drug portfolio companies, and have gradually opened clinical sites in China to join the International Multi-Center Clinical Trials (MRCT). Additionally, we are working with leading CRO providers to advance research and development drug candidates.